NASDAQ:OCAT - Ocata Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.47 0.00 (0.00 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$8.47
Today's Range$8.47 - $8.47
52-Week Range$3.06 - $8.71
VolumeN/A
Average Volume656,469 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive OCAT News and Ratings via Email

Sign-up to receive the latest news and ratings for OCAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:OCAT
CUSIPN/A
Phone+1-508-7561212

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-4,564.66%
Return on Equity-103.02%
Return on Assets-46.18%

Miscellaneous

EmployeesN/A
Outstanding Shares42,230,000
Market Cap$0.00

Ocata Therapeutics (NASDAQ:OCAT) Frequently Asked Questions

What is Ocata Therapeutics' stock symbol?

Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."

How were Ocata Therapeutics' earnings last quarter?

Ocata Therapeutics Inc (NASDAQ:OCAT) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter. Ocata Therapeutics had a negative return on equity of 103.02% and a negative net margin of 4,564.66%. View Ocata Therapeutics' Earnings History.

Has Ocata Therapeutics been receiving favorable news coverage?

Press coverage about OCAT stock has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocata Therapeutics earned a media and rumor sentiment score of 0.17 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.83 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Ocata Therapeutics.

How do I buy shares of Ocata Therapeutics?

Shares of OCAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocata Therapeutics' stock price today?

One share of OCAT stock can currently be purchased for approximately $8.47.

How can I contact Ocata Therapeutics?

Ocata Therapeutics' mailing address is 33 Locke Dr, MARLBOROUGH, MA 01752-1167, United States. The biotechnology company can be reached via phone at +1-508-7561212.


MarketBeat Community Rating for Ocata Therapeutics (NASDAQ OCAT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  149
MarketBeat's community ratings are surveys of what our community members think about Ocata Therapeutics and other stocks. Vote "Outperform" if you believe OCAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.